Clinical Trials
20 trialsNCT05819892 2026-05-20
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06840886 2026-05-14
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
NCT03932409 2026-05-08
FIERCE
University of Oklahoma
Phase 1 Active not recruiting
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07216105 2026-04-07
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT06795009 2025-12-11
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT02630823 2025-01-03
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
Phase 1 Completed
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT02788708 2022-09-19
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02269293 2021-04-23
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT02069158 2019-05-21
IOSI-NDU-001
Oncology Institute of Southern Switzerland
Phase 1 Completed
NCT01256268 2017-08-30
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01209195 2016-09-08
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Merrimack Pharmaceuticals
Phase 1 Completed
NCT00334321 2015-10-05
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
Washington University School of Medicine
Phase 1 Completed
NCT00408655 2014-06-19
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002949 2013-09-05
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
University of Chicago
Phase 1 Completed
NCT00028535 2013-06-04
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00756847 2013-04-10
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
Sanofi
Phase 1 Completed